gRNA Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Research-Use, GMP-grade), By Product & Services (Product (gRNA Final Products, gRNA Synthesis Products (gRNA Synthesis Kits, Plasmids, Others)), Custom gRNA Synthesis Services), By Application (Genome Engineering, Disease Model Studies, Functional Genomics, Epigenetics, Others), By End-Use (Pharmaceutic
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationgRNA Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Research-Use, GMP-grade), By Product & Services (Product (gRNA Final Products, gRNA Synthesis Products (gRNA Synthesis Kits, Plasmids, Others)), Custom gRNA Synthesis Services), By Application (Genome Engineering, Disease Model Studies, Functional Genomics, Epigenetics, Others), By End-Use (Pharmaceutic
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 498.23 million |
| Market Size (2029) | USD 1370.40 million |
| CAGR (2024-2029) | 18.54% |
| Fastest Growing Segment | Pharmaceutical & Biotechnology Companies |
| Largest Market | North America |
Market Overview
Key Market Drivers
Advancements in Genetic Engineering
Increased Research and Development Activities
Rising Demand for Personalized Medicine
The global gRNA (guide RNA) market is witnessing a compelling surge in demand, driven in no small part by the rising prominence of personalized medicine. As the understanding of the human genome advances, there is an increasing recognition of the potential of gRNA technology, particularly within the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) framework, to revolutionize healthcare. Personalized medicine aims to tailor medical treatments to individual genetic profiles, and gRNA plays a pivotal role in this paradigm shift. The ability of gRNA to precisely target and modify specific genes opens avenues for developing customized therapies for a spectrum of genetic disorders, ranging from rare diseases to more prevalent conditions. This demand is underscored by the quest to find targeted and effective treatments with minimal side effects, aligning with the ethos of precision medicine. The pharmaceutical industry is increasingly investing in research and development initiatives centered on gRNA applications, striving to unlock the full therapeutic potential of genome editing. The advent of CRISPR-based gene therapies for various genetic disorders has heightened interest in the gRNA market, creating a symbiotic relationship between the demand for personalized medicine and the technological capabilities of gRNA. The gRNA market, as an integral component of the personalized medicine landscape, is poised for substantial growth. The convergence of cutting-edge genetic engineering technologies with the paradigm shift towards individualized healthcare is reshaping the global healthcare landscape and positioning gRNA as a cornerstone in the quest for more effective and tailored medical interventions.
Key Market Challenges
Off-Target Effects
Delivery Methods
Key Market Trends
Therapeutic Applications
Focus on CRISPR-Cas Systems
The global gRNA (guide RNA) market is experiencing a distinct trend marked by a heightened focus on CRISPR-Cas systems. As the cornerstone of precise genome editing, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology relies on guide RNA to direct Cas proteins to specific genomic locations, enabling targeted modifications. The continuous refinement and optimization of CRISPR-Cas systems have become a focal point of research and development within the gRNA market. Scientists and biotechnologists are actively engaged in exploring novel Cas proteins, engineering existing ones for enhanced specificity, and developing alternative CRISPR systems beyond the well-known Cas9. This trend is driven by the quest for greater precision and reduced off-target effects in genome editing applications. The versatility of CRISPR-Cas systems allows researchers to tailor their approach to different genetic contexts and overcome challenges associated with specific gene-editing scenarios. The rise in interest extends beyond academic research, with biotechnology companies investing significantly in the development of CRISPR-based tools for applications in therapeutics, agriculture, and various research fields. As CRISPR-Cas systems become more sophisticated and adaptable, the gRNA market is poised to benefit from the expanding toolkit of genome editing technologies. The focus on CRISPR-Cas systems aligns with the market's pursuit of refining and advancing gRNA technology, making it an integral component in the continuous evolution of genetic engineering and its diverse applications across industries.
Segmental Insights
Product & Services Insights
Based on Product & Services, product segment dominated the Global gRNA Market in 2023. This is ascribed due to
End Use Insights
Based on end use, pharmaceutical and biotechnology companies segment dominated the Global gRNA Market in 2023. This is ascribed due to
Regional Insights
North America dominate the global gRNA market in 2023. The region's dominance is notably influenced by the significant presence of key industry players in the region. This local concentration of major players contributes to the overall growth of the gRNA industry in North
Recent Development
- In May 2023, Revvity Inc, a subsidiary of PerkinElmer, Inc., completed the acquisition of Horizon Discovery Ltd., a prominent player in life sciences and diagnostics. This strategic move solidifies Revvity Inc.'s position in the industry, enhancing its capabilities and expanding its portfolio. Concurrently, PerkinElmer’s life sciences and diagnostics division underwent a transformation, rebranding itself as Revvity. This rebranding aligns with the company's broader strategic goals of innovation and market leadership in healthcare solutions. The integration of Horizon Discovery Ltd. into Revvity Inc. signifies a synergy of expertise and resources, poised to drive advancements in biotechnological research and diagnostic technologies. Together, under the Revvity brand, they aim to accelerate scientific discoveries and deliver impactful solutions to global healthcare challenges.
- In July 2023, Sanofi and Scribe Therapeutics announced a collaboration valued at up to $1.2 billion aimed at advancing an in vivo genome editing therapy for sickle cell anemia (SCA) and other genomic diseases. This innovative therapy offers a more cost-effective alternative to ex vivo treatments for SCA. The partnership combines Sanofi's expertise in biopharmaceuticals with Scribe Therapeutics' pioneering CRISPR technology, aiming to revolutionize treatment approaches by directly targeting genetic defects within the body. This initiative underscores a commitment to addressing unmet medical needs through cutting-edge genomic medicine, potentially transforming the landscape of healthcare by offering more accessible and efficient therapies for patients affected by genetic disorders like SCA.
Key Market Players
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- System Biosciences, LLC
- Jena Bioscience GmbH
- Merck KGaA
- Azenta US, Inc.
- Takara Bio, Inc.
- Synbio Technologies
- Revvity, Inc.
- Synthego Corporation
| By Type | By Product & Services | By Application | By End Use | By Region |
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy